MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

Search

Adaptive Biotechnologies Corp

Затворен

7.88

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

7.82

Максимум

7.9

Ключови измерители

By Trading Economics

Приходи

-1.6M

-34M

Продажби

1M

47M

EPS

-0.228

Марж на печалбата

-71.044

Служители

619

EBITDA

-1.8M

-26M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+21.29% upside

Дивиденти

By Dow Jones

Следващи печалби

1.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-108M

1.1B

Предишно отваряне

7.88

Предишно затваряне

7.88

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

Adaptive Biotechnologies Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

25.04.2025 г., 17:01 ч. UTC

Печалби
Значими двигатели на пазара

Aon Shares Sink After 1Q Profit Falls, Sales Miss Estimates

25.04.2025 г., 16:10 ч. UTC

Печалби
Значими двигатели на пазара

Coursera Shares Rise After 1Q Beat, Better-Than-Expected Revenue View

26.04.2025 г., 18:14 ч. UTC

Печалби

Tech Executives Are Starting to Talk Tariffs. What It May Mean for Apple, Amazon Earnings -- Barrons.com

26.04.2025 г., 15:00 ч. UTC

Печалби
Придобивния, сливания и поглъщания

Trump 2.0 Era Brings Flurry of Crypto Deals -- WSJ

26.04.2025 г., 08:20 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

25.04.2025 г., 21:24 ч. UTC

Топ новини

Cargo Shipments From China to the U.S. Dwindle -- WSJ

25.04.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

25.04.2025 г., 20:45 ч. UTC

Топ новини

Stocks Claw Back Most of April's Tariff Losses -- WSJ

25.04.2025 г., 20:39 ч. UTC

Печалби

The Score: Tesla, Capital One, Boeing and More Stocks That Defined the Week -- WSJ

25.04.2025 г., 20:37 ч. UTC

Топ новини

Trump Administration Lays Out Tariff Roadmap to Streamline Trade Talks -- WSJ

25.04.2025 г., 20:19 ч. UTC

Топ новини

Nasdaq Climbs More Than 1% as Stocks Finish Strong Week -- WSJ

25.04.2025 г., 20:15 ч. UTC

Печалби

Week's Best: A Dividend Expert's Best Advice -- Barrons.com

25.04.2025 г., 19:23 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Extend Weekly Losses -- Market Talk

25.04.2025 г., 19:18 ч. UTC

Пазарно говорене

Oil Futures End Choppy Week With Losses -- Market Talk

25.04.2025 г., 18:47 ч. UTC

Пазарно говорене

Gold Extends Pullback to Close Week -- Market Talk

25.04.2025 г., 18:39 ч. UTC

Топ новини

Nasdaq, Dow Industrials About Flat; Analysts Caution on Trump Tariffs -- WSJ

25.04.2025 г., 18:34 ч. UTC

Придобивния, сливания и поглъщания

Goldman Sachs Upgrades Schwab Stock. Here's Why. -- Barrons.com

25.04.2025 г., 18:32 ч. UTC

Пазарно говорене
Печалби

Global Equities Roundup: Market Talk

25.04.2025 г., 18:32 ч. UTC

Пазарно говорене
Печалби

Carriers See Tariffs Driving Up Phone Prices, Slowing Upgrades -- Market Talk

25.04.2025 г., 18:08 ч. UTC

Печалби

Sphere Entertainment Deal Is a Win for Shareholders as Banks Take a Hit -- Barrons.com

25.04.2025 г., 17:55 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By 2 to 483 -- Market Talk

25.04.2025 г., 17:40 ч. UTC

Топ новини

Consumers Continue to Sour on the Economy -- 4th Update

25.04.2025 г., 17:38 ч. UTC

Печалби

Centene Stock Falls on Medicaid Cost Worries -- Barrons.com

25.04.2025 г., 17:07 ч. UTC

Пазарно говорене

Oil Futures Turn Higher in Quiet Trade -- Market Talk

25.04.2025 г., 16:54 ч. UTC

Пазарно говорене
Печалби

Mobile Carriers See Stronger Activity on Bigger Price Tags, Tariffs -- Market Talk

25.04.2025 г., 16:46 ч. UTC

Печалби

Reddit, Meta, and Pinterest Stocks Rise. How Alphabet's Earnings Are Giving Them a Boost. -- Barrons.com

25.04.2025 г., 16:20 ч. UTC

Пазарно говорене
Печалби

Basic Materials Roundup: Market Talk

25.04.2025 г., 16:12 ч. UTC

Топ новини

Dow Industrials Fall; China Plans Economic Support During Trade Battle -- WSJ

25.04.2025 г., 16:03 ч. UTC

Печалби

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25.04.2025 г., 15:52 ч. UTC

Пазарно говорене

Grains Mixed on Low Volume Trade -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Adaptive Biotechnologies Corp Прогноза

Ценова цел

By TipRanks

21.29% нагоре

12-месечна прогноза

Среден 9.57 USD  21.29%

Висок 12 USD

Нисък 7 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Adaptive Biotechnologies Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

6

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

7.39 / 8.03Подкрепа & съпротива

Краткосрочен план

Neutral Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Weak Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.